Authors



Soe Min Tun, MD, MBA, MSc

Latest:

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.



Evgenia Isachenko, PhD

Latest:

Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma

A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.


Yılmaz Tezcan, MD

Latest:

Spinal ATRT and Radiotherapy Case Report in an Adult Man

A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.


Annel Urena, RN

Latest:

Clinical Pearls on CRS and ICANS Management in Multiple Myeloma

Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.


Darlene Dobkowski, MA

Latest:

Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.



Arliene Ravelo, MPH

Latest:

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.



Ashley Chan

Latest:

Apalutamide/AAP Improves Outcomes Without Negative HRQOL Impact in Prostate Cancer

Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.


Vikram Narayan, MD

Latest:

Impact of Tobacco Cessation on the Development of Bladder Cancer

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.


Lynette M. Sholl, MD

Latest:

Sholl Examines Importance of Pathology in Cancer Care

“You have to look at the cell-free DNA results with a grain of salt and with some degree of sophistication in terms of what you can act on as a predictive biomarker in the blood.”


Jonathan Mizrahi, MD

Latest:

Expert Emphasizes Importance of Cancer Prevention and Screenings on World Cancer Day

An expert from Ochsner Health discusses the essential role positive lifestyle habits and regular screenings play in preventing cancer diagnoses.


Naveen Pemmaraju, MD

Latest:

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting

A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.


Phillip H. Kuo, MD, PhD

Latest:

Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPC

Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.


Ernest C. Quintin, MD

Latest:

Unmet Needs and Future Directions in the Management of Multiple Myeloma

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.


Aaron Falchook, MD

Latest:

Prostate Cancer Screening – What Does the Evidence Tell Us?

In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men. The justification for this recommendation was that large randomized trials demonstrated that PSA screening increased detection of prostate cancer, but there was "small to no reduction in prostate cancer-specific mortality."


Alexander Stegh, PhD

Latest:

Novel Nanomedicine Development for Glioblastoma

We spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.



Ana Aparicio, MD

Latest:

Treating AR-Indifferent Prostate Cancer

Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.


Anas Younes, MD

Latest:

Molecular Characterizations of Diffuse Large B-Cell Lymphoma

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.


Anna Azvolinsky

Latest:

PTEN Mutation Status Potential Biomarker for Endometrial Cancer Therapies

Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.


Anna Azvolinsky, PhD

Latest:

The Re-emergence of Gemtuzumab Ozogamicin for AML

In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.


Bobby Lazzara, MD

Latest:

IMDC Prognostic Category May Predict Treatment Course for Metastatic RCC Patients

A recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.


Bryant Furlow

Latest:

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.


Caroline Robert, MD, PhD

Latest:

Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.


Cesar A. Moran, MD

Latest:

Woman With a Polypoid Endometrial Tumor

A 52-year-old woman presents with a polypoid endometrial tumor. What is your diagnosis?


Charles G. Drake, MD, PhD

Latest:

ASCO: Presentation Preview on Immunotherapy Approaches for Urological Cancers

As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss some of the immunotherapy treatment options for urological cancers.


Charlotte Pawlyn, MB, BChir, PhD

Latest:

Novel Quadruplet Therapy Shows Promise in Multiple Myeloma

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.